352 related articles for article (PubMed ID: 26099670)
1. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
[TBL] [Abstract][Full Text] [Related]
2. Value of PET/CT in the management of primary hepatobiliary tumors, part 2.
Sacks A; Peller PJ; Surasi DS; Chatburn L; Mercier G; Subramaniam RM
AJR Am J Roentgenol; 2011 Aug; 197(2):W260-5. PubMed ID: 21785051
[TBL] [Abstract][Full Text] [Related]
3. Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors.
De Gaetano AM; Rufini V; Castaldi P; Gatto AM; Filograna L; Giordano A; Bonomo L
Abdom Imaging; 2012 Dec; 37(6):983-1003. PubMed ID: 22527152
[TBL] [Abstract][Full Text] [Related]
4. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
Buchmann I; Ganten TM; Haberkorn U
Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
[TBL] [Abstract][Full Text] [Related]
5. The role of (18)F-fluorodeoxyglucose positron emission tomography in the diagnosis, staging, and follow-up of cholangiocarcinoma.
Moon CM; Bang S; Chung JB
Surg Oncol; 2011 Mar; 20(1):e10-7. PubMed ID: 19804967
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
[TBL] [Abstract][Full Text] [Related]
7. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
Donswijk ML; Hess S; Mulders T; Lam MG
PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
[TBL] [Abstract][Full Text] [Related]
8. Impact of EUS-FNA for preoperative para-aortic lymph node staging in patients with pancreatobiliary cancer.
Kurita A; Kodama Y; Nakamoto Y; Isoda H; Minamiguchi S; Yoshimura K; Kuriyama K; Sawai Y; Uza N; Hatano E; Uemoto S; Togashi K; Haga H; Chiba T
Gastrointest Endosc; 2016 Sep; 84(3):467-475.e1. PubMed ID: 26970011
[TBL] [Abstract][Full Text] [Related]
9. [18F-FDG PET/CT in staging and restaging cholangiocarcinoma].
Notaristefano A; Niccoli Asabella A; Stabile Ianora AA; Merenda N; Moschetta M; Antonica F; Altini C; Ferrari C; Cesarano E; Rubini G
Recenti Prog Med; 2013; 104(7-8):328-35. PubMed ID: 24042402
[TBL] [Abstract][Full Text] [Related]
10. Comparison of magnetic resonance imaging and 18-fludeoxyglucose positron emission tomography/computed tomography in the diagnostic accuracy of staging in patients with cholangiocarcinoma: A meta-analysis.
Huang X; Yang J; Li J; Xiong Y
Medicine (Baltimore); 2020 Aug; 99(35):e20932. PubMed ID: 32871859
[TBL] [Abstract][Full Text] [Related]
11. Staging and follow-up of gastrointestinal tumors with PET/CT.
Rosenbaum SJ; Stergar H; Antoch G; Veit P; Bockisch A; Kühl H
Abdom Imaging; 2006; 31(1):25-35. PubMed ID: 16333707
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.
Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM
World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105
[TBL] [Abstract][Full Text] [Related]
13. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer.
Corvera CU; Blumgart LH; Akhurst T; DeMatteo RP; D'Angelica M; Fong Y; Jarnagin WR
J Am Coll Surg; 2008 Jan; 206(1):57-65. PubMed ID: 18155569
[TBL] [Abstract][Full Text] [Related]
14. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer.
Kato T; Tsukamoto E; Kuge Y; Katoh C; Nambu T; Nobuta A; Kondo S; Asaka M; Tamaki N
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1047-54. PubMed ID: 12173019
[TBL] [Abstract][Full Text] [Related]
15. A prospective study of the impact of fluorodeoxyglucose positron emission tomography with concurrent non-contrast CT scanning on the management of operable pancreatic and peri-ampullary cancers.
Burge ME; O'Rourke N; Cavallucci D; Bryant R; Francesconi A; Houston K; Wyld D; Eastgate M; Finch R; Hopkins G; Thomas P; Macfarlane D
HPB (Oxford); 2015 Jul; 17(7):624-31. PubMed ID: 25929273
[TBL] [Abstract][Full Text] [Related]
16. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
17. [18F]fludeoxyglucose positron emission tomography and computed tomography as a prognostic tool before liver transplantation, resection, and loco-ablative therapies for hepatocellular carcinoma.
Asman Y; Evenson AR; Even-Sapir E; Shibolet O
Liver Transpl; 2015 May; 21(5):572-80. PubMed ID: 25644857
[TBL] [Abstract][Full Text] [Related]
18. Preoperative 18F-FDG PET-CT maximum standardized uptake value predicts recurrence of biliary tract cancer.
Park MS; Lee SM
Anticancer Res; 2014 May; 34(5):2551-4. PubMed ID: 24778075
[TBL] [Abstract][Full Text] [Related]
19. Recurrent pancreatic carcinoma and cholangiocarcinoma: 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT).
Cameron K; Golan S; Simpson W; Peti S; Roayaie S; Labow D; Kostakoglu L
Abdom Imaging; 2011 Aug; 36(4):463-71. PubMed ID: 21465110
[TBL] [Abstract][Full Text] [Related]
20. Primary tumor maximum standardized uptake value measured on 18F-fluorodeoxyglucose positron emission tomography-computed tomography is a prognostic value for survival in bile duct and gallbladder cancer.
Lee JY; Kim HJ; Yim SH; Shin DS; Yu JH; Ju DY; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
Korean J Gastroenterol; 2013 Oct; 62(4):227-33. PubMed ID: 24162710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
